Profound Medical (PROF) schedules March 5, 2026 call on 2025 results

Rhea-AI Filing Summary

Profound Medical Corp. filed a current report to let investors know when it will share its next results. The company plans to release its fourth quarter and full year 2025 financial results after market close on Thursday, March 5, 2026, and will host a conference call at 4:30 p.m. Eastern Time that day to review the numbers and discuss business developments.

Profound is a commercial-stage medical device company focused on interventional MRI procedures, including its TULSA-PRO® system for prostate disease and Sonalleve® platform for non-invasive treatment of uterine fibroids, certain bone and soft-tissue conditions, and other potential oncology and hyperthermia applications.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

False000162880800016288082026-02-122026-02-12iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  February 12, 2026

_______________________________

PROFOUND MEDICAL CORP.

(Exact name of registrant as specified in its charter)

_______________________________

Ontario, Canada	001-39032	Not Applicable
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

2400 Skymark Avenue, Unit 6

Mississauga, Ontario, Canada L4W 5K5

(Address of Principal Executive Offices) (Zip Code)

Registrant's Telephone Number, Including Area Code: 647-476-1350

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Shares	PROF	The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

On February 12, 2026, Profound Medical Corp. (the “Company”) issued a press release announcing that it plans to release its fourth quarter and full year 2025 financial results after market close on Thursday, March 5, 2026, and that the Company will host a conference call to review the financial results and discuss business developments at 4:30 p.m. Eastern Time on the same day. The press release contains additional information regarding how to access the conference call and webcast. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or the Exchange Act, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, or the Securities Act. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing with the U.S. Securities Exchange Commission, or the SEC, made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release, dated February 12, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	PROFOUND MEDICAL CORP.
Date: February 12, 2026	By:	/s/ Rashed Dewan
		Rashed Dewan
		Chief Financial Officer

EXHIBIT 99.1

Profound Medical to Release Fourth Quarter and Full Year 2025 Financial Results on March 5th – Conference Call to Follow

TORONTO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, will announce its fourth quarter and full year 2025 financial results after market close on Thursday, March 5, 2026.

Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period.

Fourth Quarter and Full Year 2025 Results Conference Call Details:

Date: Thursday, March 5, 2026

Time: 4:30 p.m. ET

Live Call Registration: https://register-conf.media-server.com/register/BI9b6f3d29fd3749db83543442274147c2

The call will also be broadcast live and archived on the Company's website in the Investors section here.

About Profound Medical Corp.

Profound is a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures.

Profound is commercializing TULSA-PRO^®, a technology that combines real-time MRI, AI-enhanced planning, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA Procedure™, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (“BPH”); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. The TULSA Procedure employs real-time MR guidance for precision to preserve patients’ urinary continence and sexual function, while killing the targeted prostate tissue via precise sound absorption technology that gently heats it to 55-57°C. The TULSA Procedure is an incision- and radiation-free “one-and-done” procedure performed in a single session that takes a few hours. Virtually all prostate shapes and sizes can be safely, effectively, and efficiently treated with the TULSA Procedure. There is no bleeding associated with the procedure; no hospital stay is required; and most TULSA patients report quick recovery to their normal routine. TULSA-PRO is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (“FDA”).

Profound is also commercializing Sonalleve^®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids, adenomyosis, pain palliation of bone metastases, desmoid tumors and osteoid osteoma. Sonalleve has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma. Profound is in the early stages of exploring additional potential treatment markets for Sonalleve where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.

For further information, please contact:

Stephen Kilmer
Investor Relations
skilmer@profoundmedical.com
T: 647.872.4849

FAQ

When will Profound Medical (PROF) release Q4 and full year 2025 results?

Profound Medical will release its fourth quarter and full year 2025 financial results after market close on Thursday, March 5, 2026. The timing allows investors to review details alongside a same-day management conference call discussing performance and business developments.

What time is Profound Medical’s March 5, 2026 earnings conference call?

Profound Medical’s conference call to discuss fourth quarter and full year 2025 results is scheduled for 4:30 p.m. Eastern Time on Thursday, March 5, 2026. Management will review the financial results and outline key business developments from the period on this call.

How can investors access Profound Medical’s March 5, 2026 earnings call?

Investors can access Profound Medical’s March 5, 2026 earnings call through a live registration link provided in the announcement and via a simultaneous webcast. The call will also be archived on the company’s website in the Investors section for later listening.

What does Profound Medical Corp. (PROF) specialize in?

Profound Medical is a commercial-stage medical device company focused on innovative interventional MRI (iMRI) procedures. It is commercializing TULSA-PRO® for prostate disease treatment and Sonalleve® for non-invasive treatment of uterine fibroids, select bone and soft-tissue conditions, with exploration of additional oncology and hyperthermia uses.

What is Profound Medical’s TULSA-PRO and the TULSA Procedure?

TULSA-PRO is Profound Medical’s MRI-guided system combining real-time imaging, AI-enhanced planning, and ultrasound to ablate targeted prostate tissue. The TULSA Procedure is incision- and radiation-free, typically completed in a single session, aiming to treat a broad spectrum of prostate disease while preserving continence and sexual function.

What regulatory approvals has Profound Medical’s TULSA-PRO received?

TULSA-PRO has received CE marking in Europe, Health Canada approval, and 510(k) clearance from the U.S. Food and Drug Administration for its intended uses. These regulatory clearances allow commercial deployment of the TULSA Procedure across multiple major healthcare markets under applicable indications.

What conditions can Profound Medical’s Sonalleve platform treat?

Sonalleve is CE marked for treating uterine fibroids, adenomyosis, pain palliation of bone metastases, desmoid tumors, and osteoid osteoma. It is also approved in China for non-invasive treatment of uterine fibroids and has U.S. FDA Humanitarian Device Exemption approval for osteoid osteoma treatment.

Filing Exhibits & Attachments

5 documents

Press Releases

• EX-99.1 PRESS RELEASE 4.3 KB

Other Documents

• EX-101 XBRL SCHEMA FILE 3.3 KB
• EX-101 XBRL DEFINITION FILE 25.5 KB
• EX-101 XBRL LABEL FILE 35.1 KB
• EX-101 XBRL PRESENTATION FILE 24.1 KB